TableĀ 2

Total of patients screened each year and incidence of diabetic retinopathy (DR) and each type

20072008200920102011201220132014Significance
Total of patients with diabetes screened5027 (32.65%)4989 (32.40%)5312 (34.50%)5367 (34.86%)5276 (34.22%)6337 (41.16%)5623 (36.52%)6125 (34.42%)p=1.402
Total DR407 (8.09%)402 (8.06%)428 (8.06%)432 (8.05%)426 (8.07%)556 (8.77%)502 (8.92%)551 (8.99%)p<0.001
Classification of DR
Mild DR349 (6.94%)344 (6.89%)368 (6.92%)377 (7.02%)363 (6.88%)441 (6.96%)397 (7.06%)432 (7.05%)p<0.001
Moderate DR33 (0.65%)32 (0.64%)33 (0.62%)31 (0.58%)33 (0.62%)64 (1%)67 (1.14%)65 (1.06%)p<0.001
Severe DR24 (0.48%)26 (0.52%)26 (0.49%)24 (0.48%)30 (0.57%)47 (0.74%)43 (0.76%)46 (0.75%)p<0.001
Proliferative DR1 (0.02%)No cases1 (0.02%)No casesNo cases4 (0.06%)5 (0.08%)8 (0.13%)p<0.001
Diabetic macular oedema (DMO) study
Total DMO104 (2.00%)101 (2.02%)112 (2.11%)114 (2.12%)110 (2.08%)150 (2.36%)135 (2.40%)153 (2.49%)p<0.001
Extrafoveal DMO39 (0.75%)35 (0.72%)43 (0.84%)37 (0.69%)38 (0.72%)58 (0.92%)48 (0.86%)59 (0.96%)p<0.001
CSMO*65 (1.25%)66 (1.25%)69 (1.27%)77 (1.43%)72 (1.36%)92 (1.44%)87 (1.54%)94 (1.53%)p<0.001
Ratio CSMO/Extrafoveal DMO1.661.81.512.071.881.561.791.64p=0.142
  • The values are compared between groups using the one-way ANOVA. CSMO*, clinically significant macular oedema.